Explore by Category

Cellectis UCART Multiple Myeloma Clinical Trial Placed on Hold

MYELOMA NEWS - July 08, 2020

A Phase I CAR T clinical trial (MELANI-01) by Cellectis, a French pharmaceutical company, was placed on hold by the FDA following a myeloma patient... Read More

CelMoDs: Not Just Another Immmuno-modulatory Drug

MYELOMA NEWS - July 02, 2020

“Not just another immune-modulary drug” These are the words that Dana Farber’s Dr. Paul Richardson uses to introduce us to a new class of d... Read More

Another Bi-Specific Antibody for Multiple Myeloma Treatment

MYELOMA NEWS - July 01, 2020

It seems that hardly a week goes by without news of progress in the fight against multiple myeloma. This time it comes (again) from Johnson & Johnson, the m... Read More

A Melflufen Update in Multiple Myeloma

MYELOMA NEWS - July 01, 2020

Myeloma Crowd published a post three months ago about the work of the Swedish company Oncopeptides in treating triple refractory multiple myeloma (patients... Read More

Good News: Long Term Follow Up of Revlimid/Velcade/Dex Use

MYELOMA NEWS - June 28, 2020

We are inundated with snippets of news from a host of clinical studies reporting interesting (and even exciting) results for us, myeloma patients. The caveat wi... Read More

Which Myeloma Drug will You Respond To? Mayo Clinic Scottsdale Researchers Develop New Test

MYELOMA NEWS - June 25, 2020

Myeloma specialists and myeloma patients alike want to know which treatment will work best before they are taken. Mayo Clinic Scottsdale has developed a new tes... Read More

Progress on Another CAR -T for Multiple Myeloma!

MYELOMA NEWS - June 22, 2020

It was only a few years ago that the Myeloma Crowd started to post the first articles about CAR-T and the potential promise this medical breakthrough could be f... Read More

EHA 2020: Ixazomib is Effective as Maintenance for Transplant Ineligible Myeloma Patients

MYELOMA NEWS - June 18, 2020

Much of the maintenance therapy used in myeloma care includes immunomodulators like Revlimid or Pomalyst, but a presentation from the European Hematology Associ... Read More

ASCO 2020: CELMoDs as a New Drug Class in Multiple Myeloma

MYELOMA NEWS - June 18, 2020

A new type of myeloma treatment called CC-92480 (a CELMoD) showed benefit in a Phase I international clinical trial at the recent ASCO 2020 meeting.  ... Read More

Tocilizumab and Remdesivir Trial for COVID-19

MYELOMA NEWS - June 17, 2020

A phase III study is now open to study the COVID-19 therapies of tocilizumab alone or with remdesivir for hospitalized patients with severe COVID-19 pneumo... Read More

ASCO 2020: High-Risk Disease Progress Continues Despite Uncertainties

MYELOMA NEWS - June 11, 2020

“Despite the improvements across the board that we’ve seen in myeloma patients, high-risk disease continues to represent a more complicated arena.&r... Read More

ASCO 2020: Genetics Predict Smoldering Myeloma Progression

MYELOMA NEWS - June 11, 2020

A key study shared at the recent ASCO meeting showed that certain genetic features found in myeloma patients could help assess the risk of developing active mye... Read More

ASCO 2020: Mass Spectrometry in MRD Assessment

MYELOMA NEWS - June 03, 2020

Minimal Residual Disease (MRD) testing is used to determine the level of disease following myeloma therapy. It is a more sensitive way of testing very low level... Read More


Thanks to our site sponsors: